Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Azacitidine for Relapse Prevention Post-alloHCT in Pediatric Myeloid Malignancies
NCT03843528Phase 1Active, not recruiting
- Sponsor
- Johns Hopkins All Children's Hospital
- Start
- May 2019
- Primary completion
- Jul 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorinostat in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), mixed phenotype acute leukemia (MPAL) and 1 more, sponsored by Johns Hopkins All Children's Hospital. Primary endpoint: Maximum Tolerated Dose at 4 months. Started May 2019; status: active, not recruiting.
02
Drugs
vorinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)mixed phenotype acute leukemia (MPAL)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT03843528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843528.